176 related articles for article (PubMed ID: 22689678)
1. Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells.
Aurelius J; Martner A; Brune M; Palmqvist L; Hansson M; Hellstrand K; Thoren FB
Haematologica; 2012 Dec; 97(12):1904-8. PubMed ID: 22689678
[TBL] [Abstract][Full Text] [Related]
2. Spotlight on histamine dihydrochloride in acute myeloid leukaemia.
Yang LP; Perry CM
Drugs Aging; 2011 Apr; 28(4):325-9. PubMed ID: 21428467
[TBL] [Abstract][Full Text] [Related]
3. Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91(phox) expression and the PARP-1/PAR pathway of apoptosis.
Aurelius J; Thorén FB; Akhiani AA; Brune M; Palmqvist L; Hansson M; Hellstrand K; Martner A
Blood; 2012 Jun; 119(24):5832-7. PubMed ID: 22550344
[TBL] [Abstract][Full Text] [Related]
4. Histamine H
Monczor F; Copsel S; Fernandez N; Davio C; Shayo C
Handb Exp Pharmacol; 2017; 241():141-160. PubMed ID: 27316911
[TBL] [Abstract][Full Text] [Related]
5. NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.
Martner A; Rydström A; Riise RE; Aurelius J; Brune M; Foà R; Hellstrand K; Thorén FB
Oncotarget; 2015 Dec; 6(40):42569-74. PubMed ID: 26544512
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of myeloid cell populations during relapse-preventive immunotherapy in acute myeloid leukemia.
Rydström A; Hallner A; Aurelius J; Sander FE; Bernson E; Kiffin R; Thoren FB; Hellstrand K; Martner A
J Leukoc Biol; 2017 Aug; 102(2):467-474. PubMed ID: 28235771
[TBL] [Abstract][Full Text] [Related]
7. Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML.
Romero AI; Thorén FB; Aurelius J; Askarieh G; Brune M; Hellstrand K
Scand J Immunol; 2009 Sep; 70(3):194-205. PubMed ID: 19703009
[TBL] [Abstract][Full Text] [Related]
8. Histamine dihydrochloride: in the management of acute myeloid leukaemia.
Yang LP; Perry CM
Drugs; 2011 Jan; 71(1):109-22. PubMed ID: 21175244
[TBL] [Abstract][Full Text] [Related]
9. Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.
Thorén FB; Romero AI; Brune M; Hellstrand K
Expert Opin Biol Ther; 2009 Sep; 9(9):1217-23. PubMed ID: 19653866
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia.
Sander FE; Rydström A; Bernson E; Kiffin R; Riise R; Aurelius J; Anderson H; Brune M; Foà R; Hellstrand K; Thorén FB; Martner A
Oncotarget; 2016 Feb; 7(7):7586-96. PubMed ID: 26863635
[TBL] [Abstract][Full Text] [Related]
11. Histamine dihydrochloride for the treatment of acute myeloid leukemia, malignant melanoma and renal cell carcinoma.
Perz JB; Ho AD
Future Oncol; 2008 Apr; 4(2):169-77. PubMed ID: 18407731
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia.
Martner A; Thorén FB; Aurelius J; Söderholm J; Brune M; Hellstrand K
Expert Rev Hematol; 2010 Aug; 3(4):381-91. PubMed ID: 21083028
[TBL] [Abstract][Full Text] [Related]
13. Distinct histamine-induced cyclic AMP synthesis in acute leukemia.
Maurer WM; Litos M; Lutz D
Scand J Haematol; 1986 Nov; 37(5):438-42. PubMed ID: 3027883
[TBL] [Abstract][Full Text] [Related]
14. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial.
Brune M; Castaigne S; Catalano J; Gehlsen K; Ho AD; Hofmann WK; Hogge DE; Nilsson B; Or R; Romero AI; Rowe JM; Simonsson B; Spearing R; Stadtmauer EA; Szer J; Wallhult E; Hellstrand K
Blood; 2006 Jul; 108(1):88-96. PubMed ID: 16556892
[TBL] [Abstract][Full Text] [Related]
15. Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia.
Bernson E; Hallner A; Sander FE; Wilsson O; Werlenius O; Rydström A; Kiffin R; Brune M; Foà R; Aurelius J; Martner A; Hellstrand K; Thorén FB
Leukemia; 2017 Dec; 31(12):2552-2559. PubMed ID: 28529313
[TBL] [Abstract][Full Text] [Related]
16. Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia: a report from the Eastern Cooperative Oncology Group.
Tallman MS; Kim HT; Paietta E; Bennett JM; Dewald G; Cassileth PA; Wiernik PH; Rowe JM;
J Clin Oncol; 2004 Apr; 22(7):1276-86. PubMed ID: 14970186
[TBL] [Abstract][Full Text] [Related]
17. Leukemia-free survival as a surrogate end point for overall survival in the evaluation of maintenance therapy for patients with acute myeloid leukemia in complete remission.
Buyse M; Michiels S; Squifflet P; Lucchesi KJ; Hellstrand K; Brune ML; Castaigne S; Rowe JM
Haematologica; 2011 Aug; 96(8):1106-12. PubMed ID: 21546500
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cell receptor repertoire is comparable amongst newly diagnosed acute myeloid leukemia of different French-American-British subtypes, risk categories and chemosensitivities.
Ho X; Fook-Chong S; Linn YC
Leuk Lymphoma; 2014 Feb; 55(2):342-8. PubMed ID: 23550989
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype.
Nilsson MS; Hallner A; Brune M; Nilsson S; Thorén FB; Martner A; Hellstrand K
Hum Vaccin Immunother; 2020; 16(1):109-111. PubMed ID: 31242079
[TBL] [Abstract][Full Text] [Related]
20. Histamine and interleukin-2 in acute myelogenous leukemia.
Hellstrand K; Mellqvist UH; Wallhult E; Carneskog J; Kimby E; Celsing F; Brune M
Leuk Lymphoma; 1997 Nov; 27(5-6):429-38. PubMed ID: 9477124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
